* PMV Pharmaceuticals Inc is expected to show no change in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for PMV Pharmaceuticals Inc is for a loss of 35 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $6.00, above its last closing price of $1.65.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.35 -0.35 -0.02 Beat 94.3
Mar. 31 2024 -0.35 -0.36 -0.30 Beat 16.8
Jan. 1 0001 -0.38 -0.39 -0.31 Beat 19.7
Sep. 30 2023 -0.45 -0.45 -0.34 Beat 23.8
Jun. -0.46 -0.47 -0.38 Beat 20
30 2023
Mar. 31 2023 -0.44 -0.46 -0.42 Beat 8.4
Dec. 31 2022 -0.44 -0.44 -0.43 Beat 1.9
Sep. 30 2022 -0.43 -0.42 -0.40 Beat 5.5
This summary was machine generated November 6 at 14:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)